

Neurotech Completes \$9.0M Share Placement

Highlights:

- **Single tranche share Placement conducted following further strong clinical trial results at 20 weeks for NTI164 in children with Autism Spectrum Disorder**
- **Binding commitments for a \$9.0 million Placement with support from existing and new institutional, professional and sophisticated Australian and overseas investors**
- **Capital raised fully funds multiple Phase I/II clinical trials in PANDAS/PANS and cerebral palsy, a large Phase II/III trial in ASD and various US FDA initiatives**

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, is pleased to announce a successful \$9.0 million placement (**Placement**) to institutional, professional and sophisticated Australian and overseas investors. The Placement was conducted following the release of the Company's 20 week Phase I/II clinical trial data for daily administered oral NTI164 in children with Level II/III Autism Spectrum Disorder (ASD).

The 20 week data showed highly significant results for the most clinically important measures in ASD: severity of illness, adaptive behaviour, anxiety, depression and mood and social responsiveness. In addition, daily treatment with NTI164 showed a very acceptable safety and toxicity profile over 20 weeks with no serious adverse events reported. The data supports progression of NTI164 into a larger double blind, placebo-controlled Phase II/III trial led by Professor Michael Fahey, Head of the Paediatric Neurology Unit at Monash Medical Centre and Director of Neurogenetics.

Dr Thomas Duthy, Executive Director of Neurotech said "On behalf of the Board of Directors of Neurotech, we thank investors for their support of the Placement, and we certainly welcome the new domestic and international institutional investors to the Company. The 20 week ASD results released to ASX showed a further strong and durable clinical improvement in these difficult to treat children at 20 weeks versus 28 days and at baseline (Day 0). NTI164 was able to manage and treat the complex symptoms of ASD. Consequently, we are confident that NTI164 has the potential to be used in the clinical setting in conjunction with behavioural (non-drug) therapies to manage complex neurological symptoms in these children."

Dr Duthy continued "We eagerly await the commencement of our Phase II/III randomised, double-blind, placebo-controlled trial to confirm these important efficacy and safety findings of NTI164, and we have now lodged a Human Research Ethics Committee (HREC) application as part of our clinical commitment to further develop NTI164 in ASD. We anticipate the HREC approval and commencement of patient recruitment during Q4 CY2022 for this important study."

Placement

The Company has received binding commitments from institutional, professional and sophisticated investors totalling \$9,000,000 for the issue of 90.0 million new fully paid ordinary shares (**New Shares**). The issue price under the Placement is \$0.10 per New Share, representing a ~23% discount to the last closing price of \$0.13 immediately prior to the Company's trading halt for purposes of the Phase I/II results and capital raise, a ~10% discount to the 5 day volume weighted average price (**VWAP**) of \$0.111 and a ~4% discount to the 15 day VWAP of \$0.105.

In addition, each Placement participant will be entitled to subscribe for 1 free attaching option (**New Option**) for every 2 New Shares subscribed for under the Placement, representing a maximum issuance of 45.0 million New Options. The New Options will have a two year expiry from date of issuance and a strike price of \$0.135. It is intended the Options will be listed on the Australian Securities Exchange, subject to approvals.

The Company intends to issue the New Shares on or around Friday, 4 November 2022, with the New Options to be issued under a prospectus on or before Friday, 3 December 2022. 18,230,088 New Shares and 45,000,000 New Options will be issued under the Company's issue capacity pursuant to ASX Listing Rule 7.1, with the remaining 71,769,912 New Shares being issued under the Company's additional placement capacity pursuant to ASX Listing Rule 7.1A. Refer to the Appendix 3B lodged by the Company today for further disclosures in connection with the Placement.

The Company received cornerstone commitments totalling \$5.0 million from existing investors.

PAC Partners and Peloton Capital acted as Joint Lead Managers for the Placement.

Use of Funds

Funds raised under the placement will be applied to the Company's paediatric clinical trials program, including multiple Phase I/II trials in PANDAS/PANS and cerebral palsy, the Phase II/III clinical trial in autism spectrum disorder, drug product manufacturing and scale-up, lead-in pre-clinical work associated with the Company's planned submissions to the US Food and Drug Administration (FDA) to undertake future US trials for NT1164 and general working capital.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech is currently conducting a world-first clinical trial to assess the potential application of NT1164 for the treatment of Autism Spectrum Disorder (ASD). Results of the Phase I/II clinical trial indicated that 93% of participants had notable improvements relating to the severity of illness with no serious side effects. The next step will be initiation of a Phase II/III clinical trial to further assess the long-term safety and efficacy of NT1164, with the potential to lead to drug registration. Neurotech is also commercialising *Mente*, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

About NT1164

NT1164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. NT1164 has

been exclusively licenced from Dolce Cann Global (Ltd), for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

For personal use only